These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3281517)

  • 1. Pirmenol: preclinical pharmacology.
    Kaplan HR; Mertz TE; Steffe TJ
    Angiology; 1988 Mar; 39(3 Pt 2):281-92. PubMed ID: 3281517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacology of pirmenol.
    Kaplan HR; Mertz TE; Steffe TJ
    Am J Cardiol; 1987 Jun; 59(16):2H-9H. PubMed ID: 3591710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirmenol hydrochloride (CI-845): antiarrhythmic profile in coronary artery ligated conscious dogs.
    Mertz TE; Steffe TJ
    J Cardiovasc Pharmacol; 1980; 2(5):527-41. PubMed ID: 6157947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology and pharmacokinetics of pirmenol.
    Reiter MJ
    Angiology; 1988 Mar; 39(3 Pt 2):293-8. PubMed ID: 3281518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirmenol hydrochloride (CI-845) and reference antiarrhythmic agents: effects on early ventricular arrhythmias after acute coronary artery ligation in anesthetized rats.
    Mertz TE; Kaplan HR
    J Pharmacol Exp Ther; 1982 Nov; 223(2):580-6. PubMed ID: 7131307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiologic and antiarrhythmic actions of pirmenol on rabbit and guinea pig cardiac preparations.
    Sawanobori T; Adaniya H; Yamashita K; Kawano S; Hayami H; Kuga K; Hiraoka M
    J Cardiovasc Pharmacol; 1990 Dec; 16(6):975-83. PubMed ID: 1704993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical toxicology of pirmenol hydrochloride.
    Martin RA; de la Iglesia FA
    Angiology; 1988 Mar; 39(3 Pt 2):299-306. PubMed ID: 3354930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model systems for the discovery and development of antiarrhythmic drugs.
    Nattel S; Duker G; Carlsson L
    Prog Biophys Mol Biol; 2008; 98(2-3):328-39. PubMed ID: 19038282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pirmenol on premature atrial complexes.
    Toivonen LK
    Ann Clin Res; 1986; 18(2):106-8. PubMed ID: 3521442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of oral pirmenol.
    Ellenbogen KA; Roark SF; Sintetos AL; Smith MS; McCarthy EA; Smith WM; Kates RE; Pritchett EL
    Clin Pharmacol Ther; 1987 Oct; 42(4):405-10. PubMed ID: 3665339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pertinence of animal and human models in the evaluation of ventricular anti-arrhythmia agents].
    Funck-Brentano C; Le Heuzey JY
    Arch Mal Coeur Vaiss; 1991 Feb; 84 Spec No 2():15-20. PubMed ID: 1726994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cardiovascular effects of pirmenol with those of disopyramide in isolated canine heart preparations cross-circulated with a donor dog.
    Sugiyama A; Motomura S; Tamura K; Hashimoto K
    Jpn J Pharmacol; 1990 May; 53(1):97-110. PubMed ID: 2352380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic, electrophysiologic and hemodynamic effects of ACC-9358.
    Brown BS; Calzadilla SV; Diemer MJ; Hartman JC; Reynolds RD
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1225-34. PubMed ID: 3694532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimental arrhythmia models. Critical study of correlations with arrhythmias observed in clinical practice].
    Dupuis BA; Vincent AC
    Arch Mal Coeur Vaiss; 1981 Dec; 74 Spec No():17-27. PubMed ID: 6803699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of pirmenol enantiomers in coronary artery ligated dogs.
    Janiczek N; Smith DE; Chang T; Ventura A; Mertz TE
    J Pharm Sci; 1997 Apr; 86(4):443-9. PubMed ID: 9109046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CL-845 (pirmenol hydrochloride): a new orally effective long-acting antiarrhythmic agent.
    Steffe TJ; Mertz TE; Hastings SG; Potoczak RE; Kaplan HR
    J Pharmacol Exp Ther; 1980 Jul; 214(1):50-7. PubMed ID: 7391970
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499].
    Lynch JJ; Wallace AA; Stupienski RF; Baskin EP; Beare CM; Appleby SD; Salata JJ; Jurkiewicz NK; Sanguinetti MC; Stein RB
    J Pharmacol Exp Ther; 1994 May; 269(2):541-54. PubMed ID: 7802864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular electrophysiological effect of terikalant in the dog heart.
    Biliczki P; Acsai K; Virág L; Tálosi L; Jost N; Biliczki A; Papp JG; Varró A
    Eur J Pharmacol; 2005 Mar; 510(3):161-6. PubMed ID: 15763239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of negative inotropic and antiarrhythmic effects of class 1 antiarrhythmic drugs.
    Nawada T; Tanaka Y; Hirai S; Hisatome I; Hasegawa J; Kotake H; Mashiba H
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):347-55. PubMed ID: 7952796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Flecainide: a new antiarrhythmic agent].
    Leclercq JF; Coumel P
    Arch Mal Coeur Vaiss; 1983 Oct; 76(10):1218-30. PubMed ID: 6418100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.